LIVIVO - Search results -

Search results

Result 1 - 10 of total 54

Search options

Article ; Online: Reversible oxidation/reduction steps in the metabolic degradation of the glycerol side chain of the S1P

Treiber, Alexander / Seeland, Swen / Segrestaa, Jérôme / Lescop, Cyrille / Bolli, Martin H

Xenobiotica; the fate of foreign compounds in biological systems

2024 Volume 54, Issue 4, Page(s) 182–194

Abstract: 1. Ponesimod is a selective modulator of the sphingosine 1-phosphate receptor 1 (S1P: 2. The two major metabolic pathways give the acids M12 (-OCH: 3. Metabolic pathways for both acids were not independent and several of the transformations were ... ...

Abstract	1. Ponesimod is a selective modulator of the sphingosine 1-phosphate receptor 1 (S1P 2. The two major metabolic pathways give the acids M12 (-OCH 3. Metabolic pathways for both acids were not independent and several of the transformations were reversible, depending on reaction conditions. Formation of M13 occurred either 4. The phenol metabolite M32 was produced as part of several pathways. Control experiments at various pH values and in the absence of metabolising enzymes support the conclusion that its formation resulted from chemical degradation rather than from metabolic processes.
MeSH term(s)	Oxidation-Reduction ; Humans ; Microsomes, Liver/metabolism ; Glycerol/metabolism ; Thiazoles/metabolism ; Hepatocytes/metabolism ; Sphingosine 1 Phosphate Receptor Modulators/metabolism
Chemical Substances	ponesimod (5G7AKV2MKP) ; Glycerol (PDC6A3C0OX) ; Thiazoles ; Sphingosine 1 Phosphate Receptor Modulators
Language	English
Publishing date	2024-03-01
Publishing country	England
Document type	Journal Article
ZDB-ID	120287-x
ISSN	1366-5928 ; 0049-8254
ISSN (online)	1366-5928
ISSN	0049-8254
DOI	10.1080/00498254.2024.2319812
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 782: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The metabolism of the orexin-1 selective receptor antagonist nivasorexant.

Treiber, Alexander / Seeland, Swen / Haschimi, Belal / Weigel, Aude / Williams, Jodi T / Gabillet, Jerome

Xenobiotica; the fate of foreign compounds in biological systems

2024 Volume 54, Issue 3, Page(s) 124–137

Abstract: Nivasorexant was the first orexin-1 selective receptor antagonist entering clinical development. Despite encouraging preclinical evidence in animal models, a proof-of-concept trial in binge-eating patients recently failed to demonstrate its clinical ... ...

Abstract	Nivasorexant was the first orexin-1 selective receptor antagonist entering clinical development. Despite encouraging preclinical evidence in animal models, a proof-of-concept trial in binge-eating patients recently failed to demonstrate its clinical utility in this population.Across species, nivasorexant clearance was driven by metabolism along seven distinct pathways, five of which were hydroxylation reactions in various locations of the molecule. The exact sites of metabolism were identified by means of mass spectrometry, the use of deuterated analogues, and finally confirmed by chemical references.CYP3A4 was the main cytochrome P450 enzyme involved in nivasorexant metabolism
MeSH term(s)	Humans ; Rats ; Animals ; Aryl Hydrocarbon Hydroxylases/metabolism ; Orexins/metabolism ; Orexins/pharmacology ; Cytochrome P-450 Enzyme System/metabolism ; Hydroxylation ; Cytochrome P-450 CYP3A/metabolism ; Microsomes, Liver/metabolism ; Cytochrome P-450 CYP2C19/metabolism
Chemical Substances	Aryl Hydrocarbon Hydroxylases (EC 1.14.14.1) ; Orexins ; Cytochrome P-450 Enzyme System (9035-51-2) ; Cytochrome P-450 CYP3A (EC 1.14.14.1) ; Cytochrome P-450 CYP2C19 (EC 1.14.14.1)
Language	English
Publishing date	2024-03-01
Publishing country	England
Document type	Journal Article
ZDB-ID	120287-x
ISSN	1366-5928 ; 0049-8254
ISSN (online)	1366-5928
ISSN	0049-8254
DOI	10.1080/00498254.2024.2319811
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 782: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The metabolism of the dual orexin receptor antagonist daridorexant.

Treiber, Alexander / Delahaye, Stephane / Weigel, Aude / Aeänismaa, Päivi / Gatfield, John / Seeland, Swen

Xenobiotica; the fate of foreign compounds in biological systems

2023 Volume 53, Issue 3, Page(s) 173–183

Abstract: Daridorexant is a dual orexin receptor antagonist developed for the treatment of insomnia disorder and has shown improvement in sleep outcomes and daytime functioning. The present work describes its biotransformation ... ...

Abstract	Daridorexant is a dual orexin receptor antagonist developed for the treatment of insomnia disorder and has shown improvement in sleep outcomes and daytime functioning. The present work describes its biotransformation pathways
MeSH term(s)	Male ; Rats ; Humans ; Mice ; Animals ; Orexin Receptor Antagonists ; Imidazoles ; Sleep Initiation and Maintenance Disorders/drug therapy ; Pyrrolidines
Chemical Substances	daridorexant ; Orexin Receptor Antagonists ; Imidazoles ; Pyrrolidines
Language	English
Publishing date	2023-05-11
Publishing country	England
Document type	Journal Article
ZDB-ID	120287-x
ISSN	1366-5928 ; 0049-8254
ISSN (online)	1366-5928
ISSN	0049-8254
DOI	10.1080/00498254.2023.2183159
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 782: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Effect of nivasorexant (ACT-539313), a selective orexin-1-receptor antagonist, on multiple cytochrome P450 probe substrates in vitro and in vivo using a cocktail approach in healthy subjects.

Berger, Benjamin / Kaufmann, Priska / Berse, Matthias / Treiber, Alexander / Grignaschi, Nathalie / Dingemanse, Jasper

Pharmacology research & perspectives

2023 Volume 11, Issue 5, Page(s) e01143

Abstract: Nivasorexant, a selective orexin-1-receptor antagonist, has recently been assessed in the treatment of humans with binge-eating disorder. Herein, the inhibitory potential of nivasorexant on cytochromes P450 (CYPs) 2C9, 2C19, and 3A4 was evaluated. Human ... ...

Abstract	Nivasorexant, a selective orexin-1-receptor antagonist, has recently been assessed in the treatment of humans with binge-eating disorder. Herein, the inhibitory potential of nivasorexant on cytochromes P450 (CYPs) 2C9, 2C19, and 3A4 was evaluated. Human liver microsomes/recombinant CYP enzymes were evaluated in vitro. In vivo, a single-center, open-label, fixed-sequence study was performed in healthy adults to explore the effect of 100 mg nivasorexant administered twice daily (b.i.d.) on the pharmacokinetics (PK) of flurbiprofen (50 mg, CYP2C9), omeprazole (20 mg, CYP2C19), midazolam (2 mg, CYP3A4) making use of a cocktail approach. Plasma PK sampling was performed over 24 h on Day 1 (Cocktail alone), 8 (Cocktail + nivasorexant), and 15 (Cocktail + nivasorexant at steady state). Genotyping of subjects' CYPs was performed while safety and tolerability were also assessed. In vitro, nivasorexant inhibited CYP2C9, 2C19, and 3A4 in competitive inhibition assays with IC
MeSH term(s)	Adult ; Humans ; Cytochrome P-450 CYP2C19/genetics ; Cytochrome P-450 CYP2C9 ; Orexins ; Midazolam ; Cytochrome P-450 CYP3A Inhibitors ; Healthy Volunteers ; Flurbiprofen ; Drug Interactions ; Cytochrome P-450 Enzyme System/genetics ; Omeprazole/pharmacokinetics
Chemical Substances	Cytochrome P-450 CYP2C19 (EC 1.14.14.1) ; Cytochrome P-450 CYP2C9 (EC 1.14.13.-) ; Orexins ; Midazolam (R60L0SM5BC) ; Cytochrome P-450 CYP3A Inhibitors ; Flurbiprofen (5GRO578KLP) ; ACT-539313 ; Cytochrome P-450 Enzyme System (9035-51-2) ; Omeprazole (KG60484QX9)
Language	English
Publishing date	2023-10-06
Publishing country	United States
Document type	Journal Article
ZDB-ID	2740389-0
ISSN	2052-1707 ; 2052-1707
ISSN (online)	2052-1707
ISSN	2052-1707
DOI	10.1002/prp2.1143
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Discovery of Nivasorexant (ACT-539313): The First Selective Orexin-1 Receptor Antagonist (SO1RA) Investigated in Clinical Trials.

Williams, Jodi T / Bolli, Martin H / Brotschi, Christine / Sifferlen, Thierry / Steiner, Michel A / Treiber, Alexander / Gatfield, John / Boss, Christoph

Journal of medicinal chemistry

2024 Volume 67, Issue 4, Page(s) 2337–2348

Abstract: The orexin system consists of two neuropeptides (orexins A and B) and two receptors (OX1 and OX2). Selective OX1 receptor antagonists (SO1RA) are gaining interest for their potential use in the treatment of CNS disorders, including substance abuse, ... ...

Abstract	The orexin system consists of two neuropeptides (orexins A and B) and two receptors (OX1 and OX2). Selective OX1 receptor antagonists (SO1RA) are gaining interest for their potential use in the treatment of CNS disorders, including substance abuse, eating, obsessive compulsive, or anxiety disorders. While blocking OX2 reduces wakefulness, the expected advantage of selectively antagonizing OX1 is the ability to achieve clinical efficacy without the promotion of sleep. Herein we report our discovery efforts starting from a dual orexin receptor antagonist and describe a serendipitous finding that triggered a medicinal chemistry program that culminated in the identification of the potent SO1RA ACT-539313. Efficacy in a rat model of schedule-induced polydipsia supported the decision to select the compound as a preclinical candidate. Nivasorexant (
MeSH term(s)	Rats ; Animals ; Orexins ; Neuropeptides/pharmacology ; Orexin Receptors ; Morpholines ; Orexin Receptor Antagonists/pharmacology ; Orexin Receptor Antagonists/therapeutic use
Chemical Substances	Orexins ; ACT-539313 ; Neuropeptides ; Orexin Receptors ; Morpholines ; Orexin Receptor Antagonists
Language	English
Publishing date	2024-02-08
Publishing country	United States
Document type	Journal Article
ZDB-ID	218133-2
ISSN	1520-4804 ; 0022-2623
ISSN (online)	1520-4804
ISSN	0022-2623
DOI	10.1021/acs.jmedchem.3c01894
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 151: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MB 1: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Pyrazole derivatives as selective orexin-2 receptor antagonists (2-SORA): synthesis, structure-activity-relationship, and sleep-promoting properties in rats.

Brotschi, Christine / Bolli, Martin H / Gatfield, John / Roch, Catherine / Sifferlen, Thierry / Treiber, Alexander / Williams, Jodi T / Boss, Christoph

RSC medicinal chemistry

2023 Volume 15, Issue 1, Page(s) 344–354

Abstract: Selective orexin 2 receptor antagonists (2-SORA) such as seltorexant (15) are in clinical development for the treatment of insomnia and other conditions such as depression. Herein, we report our structure-activity-relationship (SAR) optimization efforts ... ...

Abstract	Selective orexin 2 receptor antagonists (2-SORA) such as seltorexant (15) are in clinical development for the treatment of insomnia and other conditions such as depression. Herein, we report our structure-activity-relationship (SAR) optimization efforts starting from an HTS hit (1) (
Language	English
Publishing date	2023-11-24
Publishing country	England
Document type	Journal Article
ISSN	2632-8682
ISSN (online)	2632-8682
DOI	10.1039/d3md00573a
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: CYP3A4 Catalyzes the Rearrangement of the Dual Orexin Receptor Antagonist Daridorexant to 4-Hydroxypiperidinol Metabolites.

Treiber, Alexander / Aissaoui, Hamed / Delahaye, Stéphane / Glutz, Sven / Grimont, Julien / Müller, Claus / Seeland, Swen / Siefken, Valérie / Boss, Christoph

ChemMedChem

2023 Volume 18, Issue 10, Page(s) e202300030

Abstract: The dual orexin receptor antagonist daridorexant was approved in 2022 in the USA and EU for the treatment of insomnia. The purpose of this study was the identification of its metabolic pathways and the human cytochrome P450 (P450) enzymes involved in its ...

Abstract	The dual orexin receptor antagonist daridorexant was approved in 2022 in the USA and EU for the treatment of insomnia. The purpose of this study was the identification of its metabolic pathways and the human cytochrome P450 (P450) enzymes involved in its biotransformation. With human liver microsomes, daridorexant underwent hydroxylation at the methyl group of the benzimidazole moiety, oxidative O-demethylation of the anisole to the corresponding phenol, and hydroxylation to a 4-hydroxy piperidinol derivative. While the chemical structures of the benzylic alcohol and the phenol proved to be products of standard P450 reactions, 1D and 2D NMR data of the latter hydroxylation product was incompatible with the initially postulated hydroxylation of the pyrrolidine ring and suggested the disappearance of the pyrrolidine ring and formation of a new 6-membered ring. Its formation is best explained by initial hydroxylation of the pyrrolidine ring in 5-position to yield a cyclic hemiaminal. Hydrolytic ring opening then results in an aldehyde that subsequently cyclizes onto one of the benzimidazole nitrogen atoms to yield the final 4-hydroxy piperidinol. The proposed mechanism was substantiated using an N-methylated analogue, which might hydrolyze to the open-chain aldehyde but cannot undergo the final cyclization step. CYP3A4 was the major P450 enzyme responsible for daridorexant metabolism, accounting for 89 % of metabolic turnover.
MeSH term(s)	Humans ; Cytochrome P-450 CYP3A/metabolism ; Orexin Receptor Antagonists/pharmacology ; Cytochrome P-450 Enzyme System/metabolism ; Pyrrolidines/pharmacology ; Microsomes, Liver/metabolism ; Benzimidazoles/pharmacology ; Phenols/pharmacology
Chemical Substances	Cytochrome P-450 CYP3A (EC 1.14.14.1) ; daridorexant ; Orexin Receptor Antagonists ; Cytochrome P-450 Enzyme System (9035-51-2) ; Pyrrolidines ; Benzimidazoles ; Phenols ; CYP3A4 protein, human (EC 1.14.14.55)
Language	English
Publishing date	2023-04-12
Publishing country	Germany
Document type	Journal Article
ZDB-ID	2218496-X
ISSN	1860-7187 ; 1860-7179
ISSN (online)	1860-7187
ISSN	1860-7179
DOI	10.1002/cmdc.202300030
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 6280: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Evaluating the efficacy of the selective orexin 1 receptor antagonist nivasorexant in an animal model of binge-eating disorder.

Steiner, Michel Alexander / Botticelli, Luca / Bergamini, Giorgio / Micioni Di Bonaventura, Emanuela / Gatfield, John / Williams, Jodi T / Treiber, Alexander / Vaillant, Catherine / Cifani, Carlo / Micioni Di Bonaventura, Maria Vittoria

The International journal of eating disorders

2024

Abstract: Objective: Test the efficacy of the selective orexin 1 receptor (OX1R) antagonist (SO1RA) nivasorexant in an animal model of binge-eating disorder (BED) and study its dose-response relationship considering free brain concentrations and calculated OX1R ... ...

Abstract	Objective: Test the efficacy of the selective orexin 1 receptor (OX1R) antagonist (SO1RA) nivasorexant in an animal model of binge-eating disorder (BED) and study its dose-response relationship considering free brain concentrations and calculated OX1R occupancy. Compare nivasorexant's profile to that of other, structurally diverse SO1RAs. Gain understanding of potential changes in orexin-A (OXA) neuropeptide and deltaFosB (ΔFosB) protein expression possibly underlying the development of the binge-eating phenotype in the rat model used. Method: Binge-like eating of highly palatable food (HPF) in rats was induced through priming by intermittent, repeated periods of dieting and access to HPF, followed by an additional challenge with acute stress. Effects of nivasorexant were compared to the SO1RAs ACT-335827 and IDOR-1104-2408. OXA expression in neurons and neuronal fibers as well as ΔFosB and OXA-ΔFosB co-expression was studied in relevant brain regions using immuno- or immunofluorescent histochemistry. Results: All SO1RAs dose-dependently reduced binge-like eating with effect sizes comparable to the positive control topiramate, at unbound drug concentrations selectively blocking brain OX1Rs. Nivasorexant's efficacy was maintained upon chronic dosing and under conditions involving more frequent stress exposure. Priming for binge-like eating or nivasorexant treatment resulted in only minor changes in OXA or ΔFosB expression in few brain areas. Discussion: Selective OX1R blockade reduced binge-like eating in rats. Neither ΔFosB nor OXA expression proved to be a useful classifier for their binge-eating phenotype. The current results formed the basis for a clinical phase II trial in BED, in which nivasorexant was unfortunately not efficacious compared with placebo. Public significance: Nivasorexant is a new investigational drug for the treatment of binge-eating disorder (BED). It underwent clinical testing in a phase II proof of concept trial in humans but was not efficacious compared with placebo. The current manuscript investigated the drug's efficacy in reducing binge-like eating behavior of a highly palatable sweet and fat diet in a rat model of BED, which initially laid the foundation for the clinical trial.
Language	English
Publishing date	2024-03-08
Publishing country	United States
Document type	Journal Article
ZDB-ID	603170-5
ISSN	1098-108X ; 0276-3478
ISSN (online)	1098-108X
ISSN	0276-3478
DOI	10.1002/eat.24181
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1749: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: The endothelin receptor antagonist macitentan for the treatment of pulmonary arterial hypertension: A cross-species comparison of its cytochrome P450 induction pattern.

Treiber, Alexander / Delahaye, Stephane / Seeland, Swen / Gnerre, Carmela

Pharmacology research & perspectives

2018 Volume 8, Issue 4, Page(s) e00619

Abstract: The dual endothelin receptor antagonist macitentan was approved in 2013 for the treatment of pulmonary arterial hypertension. Macitentan is an inducer of cytochrome P450 expression in vivo in animal species but not in man. In rat and dog, changes in P450 ...

Abstract	The dual endothelin receptor antagonist macitentan was approved in 2013 for the treatment of pulmonary arterial hypertension. Macitentan is an inducer of cytochrome P450 expression in vivo in animal species but not in man. In rat and dog, changes in P450 expression manifest as autoinduction upon repeat dosing. The induction pattern, however, significantly differed between both species, and between male and female rats. While macitentan exposure steadily declined with dose in the dog, P450 induction was saturable in the rat reaching levels of 40%-60% and 60%-80% at steady-state in male and female animals, respectively. The nature and number of P450 enzymes involved in macitentan clearance were identified as a major reason for the observed species differences. In the dog, macitentan was metabolized by a single P450 enzyme, that is, Cyp3a12, whereas several members of the Cyp2c and Cyp3a families were involved in the rat. Macitentan selectively upregulated Cyp3a expression in rat, whereas the expression of the Cyp2c enzymes involved in macitentan metabolism remained mostly unchanged, eventually leading to a higher contribution of Cyp3a upon induction. Macitentan also induced CYP3A4 expression in human hepatocytes via initial activation of the human pregnane X receptor. No such induction was evident in humans at the therapeutic macitentan dose of 10 mg as shown in a clinical drug-drug interaction study with the CYP3A4 substrate sildenafil.
MeSH term(s)	Animals ; Cytochrome P-450 Enzyme Inducers/administration & dosage ; Cytochrome P-450 Enzyme Inducers/pharmacology ; Dogs ; Dose-Response Relationship, Drug ; Drug Interactions ; Endothelin Receptor Antagonists/administration & dosage ; Endothelin Receptor Antagonists/pharmacology ; Enzyme Induction/drug effects ; Female ; Hepatocytes/metabolism ; Humans ; Male ; Pregnane X Receptor/drug effects ; Pregnane X Receptor/metabolism ; Pulmonary Arterial Hypertension/drug therapy ; Pyrimidines/administration & dosage ; Pyrimidines/pharmacology ; Rats ; Rats, Sprague-Dawley ; Species Specificity ; Sulfonamides/administration & dosage ; Sulfonamides/pharmacology
Chemical Substances	Cytochrome P-450 Enzyme Inducers ; Endothelin Receptor Antagonists ; NR1I2 protein, human ; Pregnane X Receptor ; Pyrimidines ; Sulfonamides ; macitentan (Z9K9Y9WMVL)
Language	English
Publishing date	2018-09-20
Publishing country	United States
Document type	Journal Article
ZDB-ID	2740389-0
ISSN	2052-1707 ; 2052-1707
ISSN (online)	2052-1707
ISSN	2052-1707
DOI	10.1002/prp2.619
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Pharmacokinetics of the selective prostacyclin receptor agonist selexipag in rats, dogs and monkeys.

Ichikawa, Tomohiko / Yamada, Tetsuhiro / Treiber, Alexander / Gnerre, Carmela / Nonaka, Kiyoko

Xenobiotica; the fate of foreign compounds in biological systems

2017 , Page(s) 1–11

Abstract: 1. This study examined the pharmacokinetics, distribution, metabolism and excretion of the selective prostacyclin receptor agonist selexipag (NS-304; ACT-293987) and its active metabolite MRE-269 (ACT-33679). The compounds were investigated following ... ...

Abstract	1. This study examined the pharmacokinetics, distribution, metabolism and excretion of the selective prostacyclin receptor agonist selexipag (NS-304; ACT-293987) and its active metabolite MRE-269 (ACT-33679). The compounds were investigated following oral and/or intravenous administration to intact rats, dogs and monkeys, and bile-duct-cannulated rats and dogs. 2. After oral administration of [
Language	English
Publishing date	2017-03-02
Publishing country	England
Document type	Journal Article
ZDB-ID	120287-x
ISSN	1366-5928 ; 0049-8254
ISSN (online)	1366-5928
ISSN	0049-8254
DOI	10.1080/00498254.2017.1294277
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 782: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito